Study of REGN 2810 Compared to Platinum-Based Chemotherapies in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC)

Exclusion Criteria

• •A patient who meets any of the following criteria will be excluded from the study:
• •1. Patients that have never smoked, defined as smoking \<100 cigarettes in a lifetime
• •2. Active or untreated brain metastases or spinal cord compression
• •3. Patients with tumors tested positive for EGFR gene mutations, ALK gene translocations, or ROS1 fusions
• •4. Encephalitis, meningitis, or uncontrolled seizures in the year prior to randomization
• •5. History of interstitial lung disease (eg, idiopathic pulmonary fibrosis, organizing pneumonia) or active, noninfectious pneumonitis that required immune-suppressive doses of glucocorticoids to assist with management. A history of radiation pneumonitis in the radiation field is permitted as long as pneumonitis resolved ≥6 months prior to randomization
• •6. Patients with active, known, or suspected autoimmune disease that has required systemic therapy in the past 2 years
• •7. Patients with a condition requiring corticosteroid therapy (\>10 mg prednisone/day or equivalent) within 14 days of randomization
• •8. Another malignancy that is progressing or requires treatment
• •9. Uncontrolled infection with hepatitis B or hepatitis C or human immunodeficiency virus (HIV) or diagnosis of immunodeficiency
• •10. Active infection requiring systemic therapy within 14 days prior to randomization
• •11. Prior therapy with anti-PD 1 or anti-PD L1
• •12. Treatment-related immune-mediated AEs from immune-modulatory agents
• •13. Receipt of an investigational drug or device within 30 days
• •14. Receipt of a live vaccine within 30 days of planned start of study medication
• •15. Major surgery or significant traumatic injury within 4 weeks prior to first dose
• •16. Documented allergic or acute hypersensitivity reaction attributed to antibody treatments
• •17. Known psychiatric or substance abuse disorder that would interfere with participation with the requirements of the study, including current use of any illicit drugs
• •18. Pregnant or breastfeeding women
• •19. Women of childbearing potential or men who are unwilling to practice highly effective contraception prior to the initial dose/start of the first treatment, during the study, and for at least 6 months after the last dose